<div id="readability-page-1"><p><span>Beta Bionics (NASDAQ:BBNX - Get Free Report)</span> had its price target cut by equities research analysts at Truist Financial  from $37.00 to $25.00 in a research note issued on Monday,Benzinga reports. The firm currently has a &#34;buy&#34; rating on the stock. Truist Financial's price objective indicates a potential upside of 80.12% from the company's current price.</p><p>A number of other equities research analysts also recently weighed in on the company. Robert W. Baird  set a $28.00 price objective on Beta Bionics in a report on Tuesday, December 16th. Lake Street Capital boosted their target price on shares of Beta Bionics from $35.00 to $40.00 and gave the company a &#34;buy&#34; rating in a research note on Friday, January 9th. Piper Sandler  reiterated an &#34;overweight&#34; rating and issued a $32.00 price objective (up previously from $26.00) on shares of Beta Bionics in a report on Wednesday, October 29th. Stifel Nicolaus  reissued a &#34;buy&#34; rating and issued a $31.00 price objective (up from $26.00) on shares of Beta Bionics in a research note on Wednesday, October 29th. Finally, Bank of America downgraded Beta Bionics from a &#34;buy&#34; rating to a &#34;neutral&#34; rating in a report on Friday, January 9th. One analyst  has rated the stock with a Strong Buy rating, six have issued  a Buy rating, four have given a Hold rating and one  has given a Sell rating to the stock. Based on data from MarketBeat, the stock  has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $27.18.</p><p><b>Read Our Latest Report on BBNX</b></p><h2>Beta Bionics Stock Up 0.4%</h2><p>Shares of NASDAQ:BBNX traded up $0.05 during trading on Monday, reaching $13.88. 70,781 shares of the company's stock traded hands, compared to its average volume of 1,462,587. The firm has a market cap of $611.14 million and a PE ratio of -3.18. Beta Bionics has a fifty-two week low of $8.89 and a fifty-two week high of $32.71. The company has a 50-day simple moving average of $25.98 and a 200-day simple moving average of $22.68. </p><h2>Insider Activity</h2><p>In related news, CFO Stephen Feider sold 20,000 shares of Beta Bionics stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $29.53, for a total transaction of $590,600.00. Following the completion of the transaction, the chief financial officer owned 42,614 shares of the company's stock, valued at $1,258,391.42. This trade represents a 31.94% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which is available at the SEC website. Also, insider Mike Mensinger sold 7,800 shares of the firm's stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $29.61, for a total value of $230,958.00. Following the transaction, the insider directly owned 82,952 shares in the company, valued at $2,456,208.72. This trade represents a 8.59% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 32,490 shares of company stock worth $960,835 over the last three months. </p><h2>Institutional Inflows and Outflows</h2><p>A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its position in  Beta Bionics by 213.5% in the 3rd quarter. Vanguard Group Inc. now owns 2,216,185 shares of the company's stock worth $44,036,000 after buying an additional 1,509,217 shares during the last quarter.  Divisadero Street Capital Management LP acquired a new stake in  Beta Bionics in the 2nd quarter valued at about $13,817,000.  Sands Capital Alternatives LLC raised its position in  Beta Bionics by 15.0% in the 2nd quarter. Sands Capital Alternatives LLC now owns 3,570,113 shares of the company's stock valued at $51,981,000 after purchasing an additional 466,331 shares in the last quarter.  Soleus Capital Management L.P. increased its stake in  Beta Bionics by 12.5% in the 2nd quarter. Soleus Capital Management L.P. now owns 3,820,158 shares of the company's stock valued at $55,622,000 after buying an additional 424,817 shares during the period.  Finally, Pura Vida Investments LLC boosted its holdings in shares of  Beta Bionics by 11,150.0% during the third quarter. Pura Vida Investments LLC now owns 281,250 shares of the company's stock worth $5,588,000 after purchasing an additional 278,750 shares during the last quarter. </p><h2>Beta Bionics Company Profile</h2> (Get Free Report)<p>Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company's flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.  </p><p>At the core of Beta Bionics' offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Beta Bionics</li><li>Trump just signed it</li><li>This is the Exact Moment the AI Boom Will End</li><li>Forget AI, This Will Be the Next Big Tech Breakthrough</li><li>ALERT: Drop these 5 stocks before the market opens tomorrow!</li><li>Refund From 1933: Trump’s Reset May Create Instant Wealth</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkJOWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkJOWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Beta Bionics Right Now?</h2><p>Before you consider Beta Bionics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Beta Bionics wasn't on the list.</p><p>While Beta Bionics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

BBNX

<p>Truist Financial has lowered its price target for Beta Bionics (NASDAQ:BBNX) from $37.00 to $25.00 while maintaining a "buy" rating. This adjustment suggests an 80.12% potential upside from the current price of $13.88. Other analysts have varied opinions, with price targets ranging from $28.00 to $40.00. The stock has a consensus rating of "Moderate Buy" and an average price target of $27.18. Recent insider trading shows significant share sales by CFO Stephen Feider and another insider, indicating a decrease in their ownership stakes.</p>

Truist Financial Has Lowered Expectations for Beta Bionics (NASDAQ:BBNX) Stock Price